We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Nearly a Quarter of Postmarket Trial Annual Reports Were Late or Not Filed in Fiscal 2020
Nearly a Quarter of Postmarket Trial Annual Reports Were Late or Not Filed in Fiscal 2020
Sponsors are still not where they should be on meeting postmarket trial requirements and commitments, the FDA’s latest analysis shows: 24 percent of annual status reports for required or agreed upon postmarket trials were either late or unfiled in fiscal 2020.